

Supplementary Table 5. Baseline characteristics of subgroup with three tumors and PS-matched cohorts for overall survival (PS cohort 1) and recurrence-free survival (PS cohort 2)

Variable	Entire patients			PS-matched cohort 1			PS-matched cohort 2			
	Total (n=134)	LR (n=20)	TACE (n=114)	P-value	LR (n=12)	TACE (n=22)	P-value	LR (n=12)	TACE (n=17)	P-value
Demographic characteristics										
Age (years)	68 (64-76)	70 (65-72)	68 (64-77)	0.74	70 (66-73)	66 (62-68)	0.08	70 (67-74)	69 (62-72)	0.58
Male	117 (87.3)	17 (85.0)	100 (87.7)	0.99	10 (83.3)	20 (90.9)	0.92	10 (83.3)	15 (88.2)	0.99
Body mass index (kg/m ²)	24.7 (22.7-26.2)	25.2 (23.7-26.5)	24.6 (22.5-26.0)	0.31	25.2 (23.9-25.3)	23.8 (22.4-25.9)	0.48	24.6 (23.5-25.6)	23.8 (22.7-26.7)	0.98
Diabetes mellitus*	28 (21.5)	4 (20.0)	24 (21.8)	0.99	2 (16.7)	4 (18.2)	0.99	1 (8.3)	3 (17.6)	0.87
Hypertension†	41 (31.1)	9 (45.0)	32 (28.6)	0.23	4 (33.3)	6 (27.3)	0.99	4 (33.3)	5 (29.4)	0.99
Alcohol										
None	33 (24.6)	6 (30.0)	27 (23.7)		5 (41.6)	5 (22.7)		5 (41.7)	5 (29.5)	
Past drinker	19 (14.2)	3 (15.0)	16 (14.0)	0.61	2 (16.7)	4 (18.2)	0.34	1 (8.3)	3 (17.6)	0.76
Current drinker	51 (38.1)	5 (25.0)	46 (40.4)		2 (16.7)	10 (45.5)		3 (25.0)	6 (35.3)	
Missing values	31 (23.1)	6 (30.0)	25 (21.9)		3 (25.0)	3 (13.6)		3 (25.0)	3 (17.6)	
Ascites										
None	123 (91.8)	18 (90.0)	105 (92.1)	0.42	11 (91.7)	22 (100.0)	0.76	10 (83.3)	17 (100.0)	0.32
Mild	7 (5.2)	2 (10.0)	5 (4.4)		1 (8.3)	0 (0.0)		2 (16.7)	0 (0.0)	
Moderate to severe	4 (3.0)	0 (0.0)	4 (3.5)		-	-		-	-	
ALBI score	-2.0 (-2.2 to 1.8)	-2.1 (-2.3 to 1.9)	-2.0 (-2.2 to 1.8)	0.06	-	-		-	-	
ALBI grade										
Grade 1/2	120 (89.6)	20 (100.0)	100 (87.7)	0.21	-	-		-	-	
Grade 3	14 (10.4)	0 (0.0)	14 (12.3)		-	-		-	-	
Laboratory findings										
Platelets (<1,000/mm ³)	104 (79-124)	120 (99-132)	100 (74-119)	0.03	123 (98-132)	113 (84-136)	0.75	113 (91-129)	101 (82-119)	0.58
AST (IU/L)	39 (29-56)	33 (26-41)	40 (30-57)	0.03	34 (28-42)	40 (28-48)	0.37	35 (30-39)	38 (30-46)	0.45
ALT (IU/L)	35 (24-50)	35 (23-51)	36 (24-50)	0.96	36 (22-45)	41 (25-50)	0.38	35 (22-51)	45 (26-54)	0.49
ALP (IU/L)	84 (66-103)	82 (62-101)	84 (66-103)	0.61	80 (68-93)	85 (66-96)	0.68	82 (68-93)	89 (72-102)	0.36
Albumin (g/dL)	3.8 (3.6-4.0)	3.8 (3.7-4.3)	3.9 (3.5-4.0)	0.04	3.8 (3.7-4.2)	3.9 (3.6-4.2)	0.99	3.9 (3.7-4.2)	3.9 (3.7-4.2)	0.96
Total bilirubin (mg/dL)	0.9 (0.7-1.3)	0.9 (0.7-1.3)	0.9 (0.7-1.4)	0.66	0.7 (0.6-1.2)	0.8 (0.7-0.9)	0.66	0.9 (0.6-1.3)	0.9 (0.8-1.3)	0.86
Total cholesterol (mg/dL)	159 (142-178)	166 (146-189)	158 (131-177)	0.23	166 (147-183)	171 (141-183)	0.86	166 (147-183)	164 (153-178)	0.89
Creatinine (mg/dL)	0.8 (0.7-0.9)	0.9 (0.7-0.9)	0.8 (0.7-0.9)	0.80	0.8 (0.7-1.0)	0.8 (0.7-0.9)	0.71	0.8 (0.7-0.9)	0.8 (0.7-0.9)	0.86
PT (INR)	1.1 (1.0-1.2)	1.1 (1.0-1.1)	1.1 (1.0-1.2)	0.01	1.1 (1.0-1.1)	1.1 (1.1-1.2)	0.50	1.1 (1.0-1.1)	1.1 (1.0-1.2)	0.36
AFP (ng/mL)	16.1 (5.4-80.2)	28.2 (4.2-147.7)	15.9 (5.4-78.6)	0.99	28.2 (5.2-48.4)	23.9 (6.0-214.8)	0.47	30.0 (5.2-98.1)	12.0 (5.9-109.2)	0.69

Supplementary Table 5. Continued

Variable	Entire patients			PS-matched cohort 1			PS-matched cohort 2			
	Total (n=134)	LR (n=20)	TACE (n=114)	P-value	LR (n=12)	TACE (n=22)	P-value	LR (n=12)	TACE (n=17)	P-value
Tumor characteristics										
Size of tumor (cm)	2.0 (1.5-2.7)	2.0 (1.5-2.7)	2.0 (1.6-2.7)	0.94	2.0 (1.4-2.7)	2.3 (2.0-2.8)	0.19	1.9 (1.4-2.7)	2.1 (1.9-2.7)	0.64

Values are presented as number (%) or median (interquartile range).

PS, propensity score; LR, liver resection; TACE, transarterial chemoembolization; ALBI, albumin-bilirubin; AST, aspartate aminotransferase; ALT, alanine aminotransferase; ALP, alkaline phosphatase; PT, prothrombin time; INR, international-normalized-ratio; AFP, alpha-fetoprotein.

*A total of four patients had missing values of diabetes mellitus in the entire cohort (four patients in TACE groups); †A total of two patients had missing values of hypertension in the entire cohort (two patients in the TACE groups).